1 662

Cited 43 times in

Diabetes mellitus mitigates cardioprotective effects of remifentanil preconditioning in ischemia-reperfused rat heart in association with anti-apoptotic pathways of survival.

DC Field Value Language
dc.contributor.author곽영란-
dc.contributor.author심연희-
dc.contributor.author이종화-
dc.contributor.author조장은-
dc.contributor.author황기철-
dc.date.accessioned2015-04-23T16:25:04Z-
dc.date.available2015-04-23T16:25:04Z-
dc.date.issued2010-
dc.identifier.issn0014-2999-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/100545-
dc.description.abstractDiabetes mellitus has been known to mitigate ischemic or pharmacologic preconditioning in ischemia-reperfusion injuries. Remifentanil is a widely used opioid in cardiac anesthesia that possesses a cardioprotective effect against ischemia-reperfusion. We evaluated whether diabetes affected remifentanil preconditioning induced cardioprotection in ischemia-reperfusion rat hearts in view of anti-apoptotic pathways of survival and Ca(2+) homeostasis. Streptozotocin-induced, diabetic rats and age-matched wild-type Sprague-Dawley rats were subjected to a left anterior descending coronary artery occlusion for 30min followed by 1h of reperfusion. Each diabetic and wild-type rat was randomly assigned to the sham, ischemia-reperfusion only, or remifentanil preconditioning group. Myocardial infarct size, activities of ERK1/2, Bcl2, Bax and cytochrome c, and gene expression influencing Ca(2+) homeostasis were assessed. Remifentanil preconditioning significantly reduced myocardial infarct size compared to ischemia-reperfusion only in wild-type rats but not in diabetic rats. Remifentanil preconditioning increased expression of ERK1/2 and anti-apoptotic protein Bcl-2 and decreased expression of pro-apoptotic proteins, Bax and cytochrome c, compared to ischemia-reperfusion only in wild-type rats. In diabetic rat hearts, however, remifentanil preconditioning failed to recover the phosphorylation state of ERK1/2 and to repress apoptotic signaling. In addition, diabetes minimized remifentanil induced modulation of abnormal changes in sarcoplasmic reticulum genes and proteins in ischemia-reperfusion rat hearts. In conclusion, diabetes mitigated remifentanil induced cardioprotection against ischemia-reperfusion, which might be associated with reduced recovery of the activities of proteins involved in anti-apoptotic pathways including ERK1/2 and the abnormal expression of sarcoplasmic reticulum genes as a result of ischemia-reperfusion in rat hearts.-
dc.description.statementOfResponsibilityopen-
dc.format.extent132~139-
dc.relation.isPartOfEUROPEAN JOURNAL OF PHARMACOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAnimals-
dc.subject.MESHApoptosis/drug effects*-
dc.subject.MESHCardiotonic Agents/pharmacology*-
dc.subject.MESHCell Survival/drug effects-
dc.subject.MESHDiabetes Mellitus*/metabolism-
dc.subject.MESHDiabetes Mellitus*/pathology-
dc.subject.MESHDiabetes Mellitus*/physiopathology-
dc.subject.MESHGene Expression Regulation/drug effects-
dc.subject.MESHHeart/drug effects*-
dc.subject.MESHHeart/physiopathology-
dc.subject.MESHHemodynamics/drug effects-
dc.subject.MESHIschemic Preconditioning, Myocardial*-
dc.subject.MESHMale-
dc.subject.MESHMitogen-Activated Protein Kinase 1/metabolism-
dc.subject.MESHMitogen-Activated Protein Kinase 3/metabolism-
dc.subject.MESHMyocardial Infarction/pathology-
dc.subject.MESHMyocardium/metabolism-
dc.subject.MESHMyocardium/pathology-
dc.subject.MESHPhosphorylation/drug effects-
dc.subject.MESHPiperidines/pharmacology*-
dc.subject.MESHRats-
dc.subject.MESHRats, Sprague-Dawley-
dc.subject.MESHReperfusion Injury/prevention & control*-
dc.subject.MESHSarcoplasmic Reticulum/drug effects-
dc.subject.MESHSarcoplasmic Reticulum/metabolism-
dc.titleDiabetes mellitus mitigates cardioprotective effects of remifentanil preconditioning in ischemia-reperfused rat heart in association with anti-apoptotic pathways of survival.-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Life Science (의생명과학부)-
dc.contributor.googleauthorHyun Soo Kim-
dc.contributor.googleauthorJang Eun Cho-
dc.contributor.googleauthorKi Chul Hwang-
dc.contributor.googleauthorYeon Hee Shim-
dc.contributor.googleauthorJung Hwa Lee-
dc.contributor.googleauthorYoung Lan Kwak-
dc.identifier.doi10.1016/j.ejphar.2009.11.032-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA00172-
dc.contributor.localIdA02196-
dc.contributor.localIdA03154-
dc.contributor.localIdA03893-
dc.contributor.localIdA04456-
dc.relation.journalcodeJ00842-
dc.identifier.eissn1879-0712-
dc.identifier.pmid19944681-
dc.identifier.urlhttp://www.sciencedirect.com/science/article/pii/S0014299909010619-
dc.subject.keywordDiabetes mellitus-
dc.subject.keywordRemifentanil-
dc.subject.keywordIschemia–reperfusion-
dc.contributor.alternativeNameKwak, Young Lan-
dc.contributor.alternativeNameShim, Yon Hee-
dc.contributor.alternativeNameLee, Jong Wha-
dc.contributor.alternativeNameCho, Jang Eun-
dc.contributor.alternativeNameHwang, Ki Chul-
dc.contributor.affiliatedAuthorKwak, Young Lan-
dc.contributor.affiliatedAuthorShim, Yon Hee-
dc.contributor.affiliatedAuthorLee, Jong Wha-
dc.contributor.affiliatedAuthorCho, Jang Eun-
dc.contributor.affiliatedAuthorHwang, Ki Chul-
dc.citation.volume628-
dc.citation.number1-3-
dc.citation.startPage132-
dc.citation.endPage139-
dc.identifier.bibliographicCitationEUROPEAN JOURNAL OF PHARMACOLOGY, Vol.628(1-3) : 132-139, 2010-
dc.identifier.rimsid36558-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > BioMedical Science Institute (의생명과학부) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Anesthesiology and Pain Medicine (마취통증의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.